[Clinical evaluation of gamma-seminoprotein as a serum marker of prostate carcinoma].
The serum levels of gamma-Seminoprotein (gamma-Sm) were determined by enzyme immunoassay in 77 patients with prostatic cancer (30 untreated and 47 treated), 44 patients with benign prostatic hypertrophy and 12 patients with prostatitis. Serum levels of gamma-Sm in each disease were as follows; untreated prostatic cancer 23.2 +/- 18.3 ng/ml (positive rate 93%), treated prostatic cancer 4.7 +/- 8.3 (positive rate 25.5%), benign prostatic hypertrophy 3.6 +/- 3.3 (positive rate 23.7%), prostatitis 2.0 +/- 2.0 (positive rate 7.7%). Serum gamma-Sm levels in prostatic cancer were higher in advanced stage but relatively low in poorly differentiated adenocarcinoma. We consider that the level of serum gamma-Sm is a useful tumor marker as well as prostatic acid phosphatase (PAP) in diagnosis and follow-up of the patients with prostatic cancer.
Sugimura
Y
Y
Department of Urology, Mie University School of Medicine.
Sakurai
M
M
Hioki
T
T
Hayashi
N
N
Yamakawa
K
K
Tajima
K
K
Tochigi
H
H
Kawamura
J
J
D000135:Acid Phosphatase / Q000097:blood; D000230:Adenocarcinoma / Q000175:diagnosis* / Q000473:pathology; D014408:Biomarkers, Tumor / Q000097:blood*; D001798:Blood Proteins; D006801:Humans; D007124:Immunoenzyme Techniques; D007564:Japan; D008297:Male; D015337:Multicenter Studies as Topic; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011467:Prostate / Q000201:enzymology; D011470:Prostatic Hyperplasia / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000473:pathology; D029584:Prostatic Secretory Proteins; D011472:Prostatitis / Q000175:diagnosis; D029589:Seminal Plasma Proteins
D014408:Biomarkers, Tumor; D001798:Blood Proteins; D029584:Prostatic Secretory Proteins; D029589:Seminal Plasma Proteins; C043076:beta-microseminoprotein; D000135:Acid Phosphatase